Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases

Abstract EN

Purpose.

Dickkopf-1 (DKK-1) and sclerostin seem to inhibit osteoblast activity by blocking the Wnt pathway, which leads to progression of metastatic prostate cancer (PC).

However, it is unknown whether serum levels of these proteins are altered in PC patients with or without metastasis.

The aim of this study was to assess DKK-1 and sclerostin serum levels in PC patients, including patients with bone metastases.

Methods.

The study cohort (N=143) consisted of 53 controls with benign prostatic hyperplasia (BPH), 43 with localized PC (PC cM0), and 47 had PC with metastasis (PC cM1).

Serum levels of DKK-1 and sclerostin were measured by enzyme-linked immunosorbent assay.

Results were compared using the Kruskal-Wallis tests; post hoc analysis was performed using the Tukey-Kramer test.

Results.

Mean DKK-1 levels in patients with BPH (2809.4 pg/ml) (p<0.001) as well as PC cM1 (2575.5 pg/ml) (p=0.001) were significantly higher than in patients with PC cN0 cM0 (1551.8 pg/ml).

Among PC cM1 patients, median DKK-1 levels were significantly lower in patients with castration-resistant disease compared to those with hormone-sensitive PC (p=0.02); in contrast, sclerostin concentrations were elevated (p=0.04).

DKK-1 correlated with PSA in the cM1 group (p=0.03) and sclerostin correlated with PSA in the PC group (0.01).

Conclusions.

DKK-1 is involved in the progression of PC.

DKK-1-mediated inhibition of osteoblasts, which contributes to tumor progression and osteolytic metastases, may also play a role in the development of metastases with osteoblastic features.

The use of DKK-1 antibodies should be considered for studies including metastatic PC patients.